当前位置:首页>产品中心>单抗/多抗>Anti-CHIKV Spike glycoprotein E2 Recombinant Antibody|抗CHIKV刺突糖蛋白E2重组抗体(靶标:基孔肯雅病毒刺突糖蛋白E2)

Anti-CHIKV Spike glycoprotein E2 Recombinant Antibody|抗CHIKV刺突糖蛋白E2重组抗体(靶标:基孔肯雅病毒刺突糖蛋白E2)

  • 货号:RB9TVK572043
  • 价格:面议
  • 点击:206

产品介绍

产品参数

形态Liquid
宿主种属Human
克隆性Monoclonal
抗体亚型IgG1, kappa
纯度>95% as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
浓度0.8 mg/ml
内毒素水平Please contact with the lab for this information.
应用ELISA, IF, WB
种属反应性Chikungunya virus
靶标Structural polyprotein, Envelope glycoprotein E2, Spike glycoprotein E2
储存缓冲液0.01M PBS, pH 7.4.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
产品使用说明ELISA: 1:2000-1:20000; WB: 1:500-1:2000
登录号Q8JUX5, Q5XXP3, Q5WQY5
背景信息Chikungunya virus (CHIKV) is an arthropod-borne alphavirus that causes Chikungunya fever, a re-emerging disease characterized by high fever, rash, and arthralgia. The E2 envelope glycoprotein is a structural protein that forms heterodimers with the E1 glycoprotein and is displayed on the viral surface as part of trimeric spike complexes. E2 is primarily responsible for receptor binding and host cell attachment, playing a key role in viral entry. As a major target of neutralizing antibodies, the E2 protein is widely used in serological diagnostics, vaccine development, and antiviral research.
备注For research use only.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Evolocumab Non-Neutralizing Recombinant Antibody |抗依洛尤单抗非中和重组抗体(靶标:依洛尤单抗非中和抗体) 451
Anti-Evolocumab Non-Neutralizing Recombinant Antibody |抗依洛尤单抗非中和重组抗体(靶标:依洛尤单抗非中和抗体) 378
Anti-Evolocumab Non-Neutralizing Recombinant Antibody |抗依洛尤单抗非中和重组抗体(靶标:依洛尤单抗非中和抗体) 292
Anti-Trastuzumab Neutralizing Recombinant Antibody |抗曲妥珠单抗中和重组抗体(靶标:曲妥珠单抗中和抗体) 463
Anti-Trastuzumab Neutralizing Recombinant Antibody |抗曲妥珠单抗中和重组抗体(靶标:曲妥珠单抗中和抗体) 530
Anti-Trastuzumab Neutralizing Recombinant Antibody |抗曲妥珠单抗中和重组抗体(靶标:曲妥珠单抗中和抗体) 557
Anti-Burosumab Neutralizing Recombinant Antibody |抗布罗索尤单抗中和重组抗体(靶标:布罗索尤单抗中和抗体) 247
Anti-Burosumab Neutralizing Recombinant Antibody |抗布罗索尤单抗中和重组抗体(靶标:布罗索尤单抗中和抗体) 279
Anti-Burosumab Non-Neutralizing Recombinant Antibody|抗布罗索尤单抗非中和重组抗体(靶标:布罗索尤单抗非中和抗体) 351
Anti-Rituximab Non-Neutralizing Recombinant Antibody |抗利妥昔单抗非中和重组抗体(靶标:利妥昔单抗非中和抗体) 404
Anti-Rituximab Non-Neutralizing Recombinant Antibody |抗利妥昔单抗非中和重组抗体(靶标:利妥昔单抗非中和抗体) 388
Anti-Rituximab Neutralizing Recombinant Antibody |抗利妥昔单抗中和重组抗体(靶标:利妥昔单抗中和抗体) 502
Anti-Rituximab Neutralizing Recombinant Antibody |抗利妥昔单抗中和重组抗体(靶标:利妥昔单抗中和抗体) 439
Anti-Zolbetuximab Non-Neutralizing Recombinant Antibody |抗佐贝妥昔单抗非中和重组抗体(靶标:佐贝妥昔单抗非中和抗体) 479
Anti-Zolbetuximab Non-Neutralizing Recombinant Antibody |抗佐贝妥昔单抗非中和重组抗体(靶标:佐贝妥昔单抗非中和抗体) 490
Anti-Zolbetuximab Non-Neutralizing Recombinant Antibody |抗佐贝妥昔单抗非中和重组抗体(靶标:佐贝妥昔单抗非中和抗体) 465
Anti-Zolbetuximab Neutralizing Recombinant Antibody |抗佐贝妥昔单抗中和重组抗体(靶标:佐贝妥昔单抗中和抗体) 246
Anti-Zolbetuximab Neutralizing Recombinant Antibody |抗佐贝妥昔单抗中和重组抗体(靶标:佐贝妥昔单抗中和抗体) 333
Anti-Zolbetuximab Neutralizing Recombinant Antibody |抗佐贝妥昔单抗中和重组抗体(靶标:佐贝妥昔单抗中和抗体) 341
Anti-Isatuximab Non-Neutralizing Recombinant Antibody |抗艾沙妥昔单抗非中和重组抗体(靶标:艾沙妥昔单抗非中和抗体) 234
总计 33037 个记录,共 1652 页,当前第 1644 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00